Evidence map›Paper›PMID 25003242›Full record

ArticleJAMA neurology2014

A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations.

Eleanna Kara, Aoife P Kiely, Christos Proukakis, Nicola Giffin, Seth Love, Jason Hehir, Khadija Rantell, Amelie Pandraud, Dena G Hernandez, Elizabeth Nacheva and 9 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in JAMA neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Pre-clinical Aspects and Contemporary Treatments of Parkinson's Disease.CNS & neurological disorders drug targets · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Aging · 2020
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Animal Models for Parkinson's Disease Research: Trends in the 2000s.International journal of molecular sciences · 2019
    Review
  19. Pure Autonomic Failure.Mayo Clinic proceedings · 2019
    Review
  20. Dementia with Lewy bodies: an update and outlook.Molecular neurodegeneration · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Eleanna KaraDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Aoife P KielyDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom2The Queen Square Brain Bank, UCL Institute of Neurology, London, United Kingdom.
Christos ProukakisDepartment of Clinical Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Nicola GiffinDepartment of Neurology, Frenchay Hospital, Bristol, United Kingdom.
Seth LoveDepartment of Neuropathology, Frenchay Hospital, Bristol, United Kingdom.
Jason HehirDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Khadija RantellBiomedical Research Centre, UCL, London, United Kingdom7Education Unit, UCL Institute of Neurology, Queen Square, London, United Kingdom.
Amelie PandraudDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Dena G HernandezDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom8Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Elizabeth NachevaDepartment of Academic Hematology, Royal Free Campus, UCL, London, United Kingdom.
Alan M PittmanDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Mike A NallsLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Andrew B SingletonLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Tamas ReveszDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom2The Queen Square Brain Bank, UCL Institute of Neurology, London, United Kingdom.
Kailash P BhatiaSobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, United Kingdom.
Niall QuinnSobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, United Kingdom.
John HardyDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Janice L HoltonDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom2The Queen Square Brain Bank, UCL Institute of Neurology, London, United Kingdom.
Henry HouldenDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom11MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom.
University College London · GBNational Hospital for Neurology and Neurosurgery · GBFrenchay Hospital · GBNational Institute on Aging · USSobell House · GBMRC Prion Unit · GBNational Institutes of Health · USThe Royal Free Hospital · GBUCL Biomedical Research Centre · GB

Funding

Genetic analysis in families with neurological diseaseZIAAG000958 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$10.9M
Genetic Analysis Of Non- Alzheimer's disease DementiasZIAAG000951 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2020
$5.6M
Genome wide SNP analysis in Parkinson's diseaseZ01AG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2006 to 2008
$2.6M
MIDCAREER AWARD IN PATIENT ORIENTED RESEARCH ON AGINGK24AG000949 · NIA · YALE UNIVERSITY · PI INOUYE, SHARON K. · 1999 to 2009
$1.4M
Intramural NIH HHS Z01 AG000949Medical Research Council G0701075Medical Research Council G0802760Medical Research Council G1001253Medical Research Council G108/638Medical Research Council MC_G1000735Medical Research Council MR/J004758/1NIA NIH HHS K24 AG000949NIA NIH HHS ZO1 AG000949-08Parkinson's UK G-0907Parkinson's UK G-1107Parkinson's UK J-0804Wellcome Trust 089698
6 · The paper itself

Abstract

importanceα-Synuclein (SNCA) locus duplications are associated with variable clinical features and reduced penetrance but the reasons underlying this variability are unknown.

objectivesTo report a novel family carrying a heterozygous 6.4 Mb duplication of the SNCA locus with an atypical clinical presentation strongly reminiscent of frontotemporal dementia and late-onset pallidopyramidal syndromes and study phenotype-genotype correlations in SNCA locus duplications. DESIGN, SETTING, AND

participantsWe report the clinical and neuropathologic features of a family carrying a 6.4 Mb duplication of the SNCA locus. To identify candidate disease modifiers, we completed a genetic analysis of the family and conducted statistical analysis on previously published cases carrying SNCA locus duplications using regression modeling with robust standard errors to account for clustering at the family level. MAIN OUTCOMES AND MEASURES: We assessed whether length of the SNCA locus duplication influences disease penetrance and severity and whether extraduplication factors have a disease-modifying role.

resultsWe identified a large 6.4 Mb duplication of the SNCA locus in this family. Neuropathological analysis showed extensive α-synuclein pathology with minimal phospho-tau pathology. Genetic analysis showed an increased burden of Parkinson disease-related risk factors and the disease-predisposing H1/H1 microtubule-associated protein tau haplotype. Statistical analysis of previously published cases suggested there is a trend toward increasing disease severity and disease penetrance with increasing duplication size. The corresponding odds ratios from the univariable analyses were 1.17 (95% CI, 0.81-1.68) and 1.34 (95% CI, 0.78-2.31), respectively. Sex was significantly associated with both disease risk and severity; men compared with women had increased disease risk and severity and the corresponding odds ratios from the univariable analyses were 8.36 (95% CI, 1.97-35.42) and 5.55 (95% CI, 1.39-22.22), respectively. CONCLUSIONS AND RELEVANCE: These findings further expand the phenotypic spectrum of SNCA locus duplications. Increased dosage of genes located within the duplicated region probably cannot increase disease risk and disease severity without the contribution of additional risk factors. Identification of disease modifiers accounting for the substantial phenotypic heterogeneity of patients with SNCA locus duplications could provide insight into molecular events involved in α-synuclein aggregation.

Indexed as

Age of Onsetalpha-SynucleinBrainFemaleFrontotemporal DementiaGene DosageGene DuplicationGenetic Association StudiesGenetic LociGenetic Predisposition to DiseaseHumansMicrosatellite RepeatsMiddle AgedOdds RatioParkinsonian DisordersPedigreealpha-Synuclein

Identifiers

PMID25003242
PMCPMC4362700
OpenAlexW2022289010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.